First multi-epitope subunit vaccine against extraintestinal pathogenic Escherichia coli delivered by a bacterial type-3 secretion system (T3SS)

International Journal of Medical Microbiology

Volumn 302, Issue 1, 2012, Pages 10-18

  Wieser, Andreas ^a   Magistro, Giuseppe ^a   Nörenberg, Dominik ^a   Hoffmann, Christiane ^a   Schubert, Sören ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Epitope; ExPEC; Extraintestinal pathogenic E. coli; Outer membrane protein; Peritonitis; Salmonella; Siderophore receptors; T3SS; Urinary tract infection; Vaccine

Indexed keywords

BACTERIAL VACCINE; EPITOPE;

ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; ESCHERICHIA COLI INFECTION; HOST CELL; MACROPHAGE; NONHUMAN; PATHOGENIC ESCHERICHIA COLI; PROTEIN EXPRESSION; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM; T LYMPHOCYTE; TYPE III SECRETION SYSTEM; VACCINATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL LOAD; BACTERIAL SECRETION SYSTEMS; EPITOPES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; ESCHERICHIA COLI VACCINES; FEMALE; GOATS; HUMANS; MALE; MICE; PROTEIN STRUCTURE, TERTIARY; SALMONELLA; SEPSIS; VACCINATION; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRULENCE;

EID: 81255161717     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2011.09.012     Document Type: Article

References (44)

1. Alteri C.J., Hagan E.C., Sivick K.E., Smith S.N., Mobley H.L. Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLoS Pathog. 2009, 5:e1000586.
2. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001, 29:1303-1310.
3. Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., Struhl K. Current Protocols in Molecular Biology 2005, John Wiley & Sons, Inc., New York, NY.
4. Baier W., Sedelmeier E.A., Bessler W.G. Studies on the immunogenicity of an Escherichia coli extract after oral application in mice. Arzneimittelforschung 1997, 47:980-985.
5. Caracciolo A., Bettinelli A., Bonato C., Isimbaldi C., Tagliabue A., Longoni L., Bianchetti M.G. Antimicrobial resistance among Escherichia coli that cause childhood community-acquired urinary tract infections in Northern Italy. Ital. J. Pediatr. 2011, 37:3.
6. Domenech V.E., Panthel K., Meinel K.M., Russmann H. Rapid clearance of a recombinant Salmonella vaccine carrier prevents enhanced antigen-specific CD8 T-cell responses after oral boost immunizations. Microbes Infect. 2005, 7:860-866.
7. Durant L., Metais A., Soulama-Mouze C., Genevard J.M., Nassif X., Escaich S. Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli. Infect. Immun. 2007, 75:1916-1925.
8. Duriez P., Clermont O., Bonacorsi S., Bingen E., Chaventre A., Elion J., Picard B., Denamur E. Commensal Escherichia coli isolates are phylogenetically distributed among geographically distinct human populations. Microbiology 2001, 147:1671-1676.
9. Fluit A.C., Verhoef J., Schmitz F.J. Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998. Eur. J. Clin. Microbiol. Infect. Dis. 2001, 20:617-625.
10. Geginat G., Nichterlein T., Kretschmar M., Schenk S., Hof H., Lalic-Multhaler M., Goebel W., Bubert A. Enhancement of the Listeria monocytogenes p60-specific CD4 and CD8 T cell memory by nonpathogenic Listeria innocua. J. Immunol. 1999, 162:4781-4789.
11. Gupta K., Hooton T.M., Stamm W.E. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann. Intern. Med. 2001, 135:41-50.
12. Gupta K., Hooton T.M., Wobbe C.L., Stamm W.E. The prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in young women. Int. J. Antimicrob. Agents 1999, 11:305-308.
13. Hachen H.J. Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial. J. Urol. 1990, 143:759-762.
14. Hopkins W.J., Elkahwaji J., Beierle L.M., Leverson G.E., Uehling D.T. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J. Urol. 2007, 177:1349-1353.
15. Johnson J.R., Russo T.A. Extraintestinal pathogenic Escherichia coli: "the other bad E. coli" J. Lab. Clin. Med. 2002, 139:155-162.
16. Jones-Carson J., Balish E., Uehling D.T. Susceptibility of immunodeficient gene-knockout mice to urinary tract infection. J. Urol. 1999, 161:338-341.
17. Konjufca V., Jenkins M., Wang S., Juarez-Rodriguez M.D., Curtiss R. Immunogenicity of recombinant attenuated Salmonella enterica serovar Typhimurium vaccine strains carrying a gene that encodes Eimeria tenella antigen SO7. Infect. Immun. 2008, 76:5745-5753.
18. Kruze D., Biro K., Holzbecher K., Andrial M., Bossart W. Protection by a polyvalent vaccine against challenge infection and pyelonephritis. Urol. Res. 1992, 20:177-181.
19. Kurazono H., Nakano M., Yamamoto S., Ogawa O., Yuri K., Nakata K., Kimura M., Makino S., Nair G.B. Distribution of the usp gene in uropathogenic Escherichia coli isolated from companion animals and correlation with serotypes and size-variations of the pathogenicity island. Microbiol. Immunol. 2003, 47:797-802.
20. Kurazono H., Yamamoto S., Nakano M., Nair G.B., Terai A., Chaicumpa W., Hayashi H. Characterization of a putative virulence island in the chromosome of uropathogenic Escherichia coli possessing a gene encoding a uropathogenic-specific protein. Microb. Pathog. 2000, 28:183-189.
21. Langermann S., Ballou W.R. Vaccination utilizing the FimCH complex as a strategy to prevent Escherichia coli urinary tract infections. J. Infect. Dis. 2001, 183(Suppl. 1):S84-S86.
22. Langermann S., Mollby R., Burlein J.E., Palaszynski S.R., Auguste C.G., DeFusco A., Strouse R., Schenerman M.A., Hultgren S.J., Pinkner J.S., Winberg J., Guldevall L., Soderhall M., Ishikawa K., Normark S., Koenig S. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J. Infect. Dis. 2000, 181:774-778.
23. Masters J.R., Hepburn P.J., Walker L., Highman W.J., Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.R., Franks L.M. Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res. 1986, 46:3630-3636.
24. McBean M., Rajamani S. Increasing rates of hospitalization due to septicemia in the US elderly population, 1986-1997. J. Infect. Dis. 2001, 183:596-603.
25. Minino A.M., Anderson R.N., Fingerhut L.A., Boudreault M.A., Warner M. Deaths: injuries, 2002. Natl. Vital Stat. Rep. 2006, 54:1-124.
26. Mobley H.L., Green D.M., Trifillis A.L., Johnson D.E., Chippendale G.R., Lockatell C.V., Jones B.D., Warren J.W. Pyelonephritogenic Escherichia coli and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains. Infect. Immun. 1990, 58:1281-1289.
27. O'Hanley P., Lalonde G., Ji G. Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis. Infect. Immun. 1991, 59:1153-1161.
28. Obert S., O'Connor R.J., Schmid S., Hearing P. The adenovirus E4-6/7 protein transactivates the E2 promoter by inducing dimerization of a heteromeric E2F complex. Mol. Cell. Biol. 1994, 14:1333-1346.
29. Reigstad C.S., Hultgren S.J., Gordon J.I. Functional genomic studies of uropathogenic Escherichia coli and host urothelial cells when intracellular bacterial communities are assembled. J. Biol. Chem. 2007, 282:21259-21267.
30. Roberts J.A. Unconventional immunology and urinary tract infection. J. Urol. 1999, 161:3.
31. Russmann H. Yersinia outer protein E, YopE. A versatile type III effector molecule for cytosolic targeting of heterologous antigens by attenuated Salmonella. Adv. Exp. Med. Biol. 2003, 529:407-413.
32. Russmann H., Shams H., Poblete F., Fu Y., Galan J.E., Donis R.O. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 1998, 281:565-568.
33. Russo T.A., Beanan J.M., Olson R., Genagon S.A., Macdonald U., Cope J.J., Davidson B.A., Johnston B., Johnson J.R. A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate. Vaccine 2007, 25:3859-3870.
34. Russo T.A., Johnson J.R. Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC. J. Infect. Dis. 2000, 181:1753-1754.
35. Russo T.A., Johnson J.R. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect. 2003, 5:449-456.
36. Russo T.A., McFadden C.D., Carlino-MacDonald U.B., Beanan J.M., Olson R., Wilding G.E. The siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate. Infect. Immun. 2003, 71:7164-7169.
37. Schmidhammer S., Ramoner R., Holtl L., Bartsch G., Thurnher M., Zelle-Rieser C. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology 2002, 60:521-526.
38. Sette A., Newman M., Livingston B., McKinney D., Sidney J., Ishioka G., Tangri S., Alexander J., Fikes J., Chesnut R. Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. Tissue Antigens 2002, 59:443-451.
39. Snyder J.A., Haugen B.J., Buckles E.L., Lockatell C.V., Johnson D.E., Donnenberg M.S., Welch R.A., Mobley H.L. Transcriptome of uropathogenic Escherichia coli during urinary tract infection. Infect. Immun. 2004, 72:6373-6381.
40. Thumbikat P., Waltenbaugh C., Schaeffer A.J., Klumpp D.J. Antigen-specific responses accelerate bacterial clearance in the bladder. J. Immunol. 2006, 176:3080-3086.
41. Vijh S., Pamer E.G. Immunodominant and subdominant CTL responses to Listeria monocytogenes infection. J. Immunol. 1997, 158:3366-3371.
42. Wang R.F., Kushner S.R. Construction of versatile low-copy-number vectors for cloning, sequencing and gene expression in Escherichia coli. Gene 1991, 100:195-199.
43. Wieser A., Romann E., Magistro G., Hoffmann C., Norenberg D., Weinert K., Schubert S. A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice. Infect. Immun. 2010, 78:3432-3442.
44. Zahar J.R., Lortholary O., Martin C., Potel G., Plesiat P., Nordmann P. Addressing the challenge of extended-spectrum beta-lactamases. Curr. Opin. Investig. Drugs 2009, 10:172-180.